Tetrabutylammonium Fluoride → 4-(6-Ethynyl-3-methylindazol-1-yl)pyrimidin-2-amine
反応式
[CH3:1][C:2]1[C:10]2[C:5](=[CH:6][C:7]([C:11]#[C:12][Si](C)(C)C)=[CH:8][CH:9]=2)[N:4]([C:17]2[CH:22]=[CH:21][N:20]=[C:19]([NH2:23])[N:18]=2)[N:3]=1.CCCC[N+](CCCC)(CCCC)CCCC.[F-]>C1COCC1>[C:11]([C:7]1[CH:6]=[C:5]2[C:10]([C:2]([CH3:1])=[N:3][N:4]2[C:17]2[CH:22]=[CH:21][N:20]=[C:19]([NH2:23])[N:18]=2)=[CH:9][CH:8]=1)#[CH:12]参加物
4
実験手順
To a solution of 4-{3-methyl-6-[2-(trimethylsilyl)ethynyl]indazol-1-yl}pyrimidin-2-amine (600 mg, 1.87 mmol) in THF (15 ml) was added TBAF (2.24 mL of a 1M solution in THF, 2.24 mmol) and the reaction mixture was allowed to stand for 0.5 hr. The reaction mixture was concentrated in vacuo, DCM (5 ml) was added and the concentration repeated (×2). The crude product was purified by flash chromatography (Biotage, 3-10% methanol in DCM) to give the title intermediate as a yellow solid (300 mg): 1H NMR (500 MHz, DMSO) delta 2.58 (3H, s), 4.37 (1H, s), 7.14-6.86 (3H, m), 7.40 (1H, dd, J=8.2, 1.1 Hz), 7.85 (1H, d, J=8.2 Hz), 8.26 (1H, d, J=5.5 Hz), 8.98 (1H, s); LC-MS: m/z=+250.35 (M+H)+.